KeyCorp Weighs in on Icon Plc’s Q4 2017 Earnings (ICLR)

Icon Plc (NASDAQ:ICLR) – Research analysts at KeyCorp dropped their Q4 2017 earnings estimates for Icon in a report issued on Tuesday. KeyCorp analyst D. Hooker now expects that the medical research company will post earnings per share of $1.39 for the quarter, down from their prior forecast of $1.41. KeyCorp has a “Buy” rating and a $130.00 price objective on the stock.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.32 by $0.03. The business had revenue of $440.30 million for the quarter, compared to analysts’ expectations of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. The firm’s revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.19 EPS.

A number of other equities research analysts have also recently issued reports on ICLR. Zacks Investment Research cut shares of Icon from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. ValuEngine cut shares of Icon from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Jefferies Group upped their price target on shares of Icon from $122.00 to $132.00 and gave the company a “buy” rating in a research note on Monday, October 9th. Barclays upped their price target on shares of Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a research note on Friday, October 27th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $123.00 price target on shares of Icon in a research note on Thursday, October 12th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Icon has an average rating of “Buy” and an average price target of $121.82.

Shares of Icon (NASDAQ:ICLR) opened at $113.27 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90. Icon has a 52-week low of $76.46 and a 52-week high of $124.48. The company has a market cap of $6,120.00, a PE ratio of 21.99, a price-to-earnings-growth ratio of 1.63 and a beta of 0.61.

Several large investors have recently made changes to their positions in the business. Acrospire Investment Management LLC boosted its position in shares of Icon by 20.1% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after acquiring an additional 200 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Icon during the 3rd quarter worth approximately $148,000. Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Icon during the 2nd quarter worth approximately $208,000. Commonwealth Equity Services Inc acquired a new stake in shares of Icon during the 3rd quarter worth approximately $208,000. Finally, Holderness Investments Co. acquired a new stake in shares of Icon during the 3rd quarter worth approximately $216,000. Hedge funds and other institutional investors own 89.66% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/14/keycorp-weighs-in-on-icon-plcs-q4-2017-earnings-iclr.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply